155 related articles for article (PubMed ID: 31611355)
1. Antiretroviral Penetration across Three Preclinical Animal Models and Humans in Eight Putative HIV Viral Reservoirs.
Devanathan AS; Pirone JR; Akkina R; Remling-Mulder L; Luciw P; Adamson L; Garcia JV; Kovarova M; White NR; Schauer AP; Blake K; Sykes C; Burgunder EM; Srinivas N; Rosen EP; Kashuba ADM
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611355
[TBL] [Abstract][Full Text] [Related]
2. Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.
Karris MY; Jain S; Bowman VQ; Rieg G; Goicoechea M; Dube MP; Kerkar S; Kemper C; Diamond C; Sun X; Daar ES; Haubrich RH; Morris S;
J Acquir Immune Defic Syndr; 2016 Jun; 72(2):e48-50. PubMed ID: 26977746
[No Abstract] [Full Text] [Related]
3. Assessing the lymphoid tissue bioavailability of antiretrovirals in human primary lymphoid endothelial cells and in mice.
Dyavar SR; Gautam N; Podany AT; Winchester LC; Weinhold JA; Mykris TM; Campbell KM; Alnouti Y; Fletcher CV
J Antimicrob Chemother; 2019 Oct; 74(10):2974-2978. PubMed ID: 31335938
[TBL] [Abstract][Full Text] [Related]
4. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.
Cahn P; Kaplan R; Sax PE; Squires K; Molina JM; Avihingsanon A; Ratanasuwan W; Rojas E; Rassool M; Bloch M; Vandekerckhove L; Ruane P; Yazdanpanah Y; Katlama C; Xu X; Rodgers A; East L; Wenning L; Rawlins S; Homony B; Sklar P; Nguyen BY; Leavitt R; Teppler H;
Lancet HIV; 2017 Nov; 4(11):e486-e494. PubMed ID: 28918877
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention.
Yap PK; Loo Xin GL; Tan YY; Chellian J; Gupta G; Liew YK; Collet T; Dua K; Chellappan DK
J Pharm Pharmacol; 2019 Sep; 71(9):1339-1352. PubMed ID: 31144296
[TBL] [Abstract][Full Text] [Related]
6. Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.
Stella-Ascariz N; Montejano R; Rodriguez-Centeno J; Alejos B; Schwimmer C; Bernardino JI; Rodes B; Allavena C; Hoffmann C; Gisslén M; de Miguel R; Esteban-Cantos A; Wallet C; Raffi F; Arribas JR;
J Infect Dis; 2018 Oct; 218(10):1523-1530. PubMed ID: 29982509
[TBL] [Abstract][Full Text] [Related]
7. Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
Pradat P; Durant J; Brochier C; Trabaud MA; Cottalorda-Dufayard J; Izopet J; Raffi F; Lucht F; Gagnieu MC; Gatey C; Jacomet C; Vassallo M; Dellamonica P; Cotte L;
J Antimicrob Chemother; 2016 Nov; 71(11):3235-3241. PubMed ID: 27432606
[TBL] [Abstract][Full Text] [Related]
8. First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2).
Matheron S; Descamps D; Gallien S; Besseghir A; Sellier P; Blum L; Mortier E; Charpentier C; Tubiana R; Damond F; Peytavin G; Ponscarme D; Collin F; Brun-Vezinet F; Chene G;
Clin Infect Dis; 2018 Sep; 67(8):1161-1167. PubMed ID: 29590335
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy.
Pain JB; Lê MP; Caseris M; Amiel C; Lassel L; Charpentier C; Desnoyer A; Farnoux C; Pialoux G; Descamps D; Peytavin G
Antimicrob Agents Chemother; 2015; 59(6):3660-2. PubMed ID: 25845873
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tissue distribution of tenofovir, emtricitabine and dolutegravir in mice.
Labarthe L; Gelé T; Gouget H; Benzemrane MS; Le Calvez P; Legrand N; Lambotte O; Le Grand R; Bourgeois C; Barrail-Tran A
J Antimicrob Chemother; 2022 Mar; 77(4):1094-1101. PubMed ID: 35022753
[TBL] [Abstract][Full Text] [Related]
11. A cross-species comparison of antiretroviral penetration into lymph nodes using novel physiologically based pharmacokinetic models.
Scholz EMB; Cao Y; Kashuba ADM
J Antimicrob Chemother; 2021 Oct; 76(11):2890-2893. PubMed ID: 34374767
[TBL] [Abstract][Full Text] [Related]
12. Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.
Guillemi SA; Ling SH; Dahlby JS; Yip B; Zhang W; Hull MW; Lima VD; Hogg RS; Werb R; Montaner JS; Harris M
J Int AIDS Soc; 2016; 19(1):20995. PubMed ID: 27624144
[TBL] [Abstract][Full Text] [Related]
13. Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study.
Aebi-Popp K; Kahlert CR; Crisinel PA; Decosterd L; Saldanha SA; Hoesli I; Martinez De Tejada B; Duppenthaler A; Rauch A; Marzolini C;
J Antimicrob Chemother; 2022 Nov; 77(12):3436-3442. PubMed ID: 36177836
[TBL] [Abstract][Full Text] [Related]
14. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
[TBL] [Abstract][Full Text] [Related]
15. Antiretroviral Drug Concentrations in Lymph Nodes: A Cross-Species Comparison of the Effect of Drug Transporter Expression, Viral Infection, and Sex in Humanized Mice, Nonhuman Primates, and Humans.
Burgunder E; Fallon JK; White N; Schauer AP; Sykes C; Remling-Mulder L; Kovarova M; Adamson L; Luciw P; Garcia JV; Akkina R; Smith PC; Kashuba ADM
J Pharmacol Exp Ther; 2019 Sep; 370(3):360-368. PubMed ID: 31235531
[TBL] [Abstract][Full Text] [Related]
16. Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
Kelesidis T; Moser C; Stein JH; Brown TT; Tran TT; Ribaudo HJ; Dube MP; Yang OO; Currier JS; McComsey GA
J Infect Dis; 2016 Sep; 214(5):748-52. PubMed ID: 27354367
[TBL] [Abstract][Full Text] [Related]
17. Determinants of blood telomere length in antiretroviral treatment-naïve HIV-positive participants enrolled in the NEAT 001/ANRS 143 clinical trial.
Alejos B; Stella-Ascariz N; Montejano R; Rodriguez-Centeno J; Schwimmer C; Bernardino JI; Rodes B; Esser S; Goujard C; Sarmento-Castro R; De Miguel R; Esteban-Cantos A; Wallet C; Raffi F; Arribas JR;
HIV Med; 2019 Nov; 20(10):691-698. PubMed ID: 31532902
[TBL] [Abstract][Full Text] [Related]
18. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
J Virol; 2018 May; 92(9):. PubMed ID: 29444937
[TBL] [Abstract][Full Text] [Related]
19. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
[TBL] [Abstract][Full Text] [Related]
20. Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.
Chéret A; Nembot G; Mélard A; Lascoux C; Slama L; Miailhes P; Yeni P; Abel S; Avettand-Fenoel V; Venet A; Chaix ML; Molina JM; Katlama C; Goujard C; Tamalet C; Raffi F; Lafeuillade A; Reynes J; Ravaux I; Hoën B; Delfraissy JF; Meyer L; Rouzioux C;
Lancet Infect Dis; 2015 Apr; 15(4):387-96. PubMed ID: 25701561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
